Akari Therapeutics, Plc announced that it has entered into a definitive agreement with individual investors such as Ray Prudo and Samir R. Patel, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 4,029,754 unregistered American Depository Shares each representing 2,000 of the Company?s ordinary shares and Series C Warrants to purchase up to 4,029,754 ADSs, at a per unit price of $1.885 per ADS and Warrant for the aggregate gross proceeds of $15,192,172 on May 29, 2024.